Article

CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells

ML Laboratories PLC-Research Division, MED IC4, Keele University Science and Business Park, Keele, Staffordshire, ST5 5SP, UK.
BMC Biotechnology (Impact Factor: 2.59). 02/2005; 5:17. DOI: 10.1186/1472-6750-5-17
Source: PubMed

ABSTRACT The hCMV promoter is very commonly used for high level expression of transgenes in mammalian cells, but its utility is hindered by transcriptional silencing. Large genomic fragments incorporating the CpG island region of the HNRPA2B1 locus are resistant to transcriptional silencing.
In this report we describe studies on the use of a novel series of vectors combining the HNRPA2B1 CpG island with the hCMV promoter for expression of transgenes in CHO-K1 cells. We show that the CpG island gives at least twenty-fold increases in the levels of EGFP and EPO observed in pools of transfectants, and that transgene expression levels remain high in such pools for more than 100 generations. These novel vectors also allow facile isolation of clonal CHO-K1 cell lines showing stable, high-level transgene expression.
Vectors incorporating the hnRPA2B1 CpG island give major benefits in transgene expression from the hCMV promoter, including substantial improvements in the level and stability of expression. The utility of these vectors for the improved production of recombinant proteins in CHO cells has been demonstrated.

Download full-text

Full-text

Available from: Michael N Antoniou, May 09, 2014
1 Follower
 · 
186 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Congenital diseases are responsible for over a third of all pediatric hospital admissions. Advances in prenatal screening and molecular diagnosis have allowed the detection of many life-threatening genetic diseases early in gestation. In utero transplantation (IUT) with stem cells could cure affected fetuses but so far in humans, successful IUT using allogeneic hematopoietic stem cells (HSCs), has been limited to fetuses with severe immunologic defects and more recently IUT with allogeneic mesenchymal stem cell transplantation, has improved phenotype in osteogenesis imperfecta. The options of preemptive treatment of congenital diseases in utero by stem cell or gene therapy changes the perspective of congenital diseases since it may avoid the need for postnatal treatment and reduce future costs. Amniotic fluid stem (AFS) cells have been isolated and characterized in human, mice, rodents, rabbit, and sheep and are a potential source of cells for therapeutic applications in disorders for treatment prenatally or postnatally. Gene transfer to the cells with long-term transgenic protein expression is feasible. Recently, pre-clinical autologous transplantation of transduced cells has been achieved in fetal sheep using minimally invasive ultrasound guided injection techniques. Clinically relevant levels of transgenic protein were expressed in the blood of transplanted lambs for at least 6 months. The cells have also demonstrated the potential of repair in a range of pre-clinical disease models such as neurological disorders, tracheal repair, bladder injury, and diaphragmatic hernia repair in neonates or adults. These results have been encouraging, and bring personalized tissue engineering for prenatal treatment of genetic disorders closer to the clinic.
    Frontiers in Pharmacology 12/2014; 5. DOI:10.3389/fphar.2014.00270
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Notwithstanding recent successes, insertional mutagenesis as well as silencing and variegation of transgene expression still represent considerable obstacles to hematopoietic gene therapy. This also applies to O(6)-methylguanine DNA methyltransferase (MGMT)-mediated myeloprotection, a concept recently proven clinically effective in the context of glioblastoma therapy. To improve on this situation we here evaluate a SIN-lentiviral vector expressing the MGMT(P140K)-cDNA from a combined A2UCOE/PGK-promoter. In a murine in vivo chemoselection model the A2UCOE.PGK.MGMT construct allowed for significant myeloprotection as well as robust and stable selection of transgenic hematopoietic cells. In contrast, only transient enrichment and severe myelotoxicity was observed for a PGK.MGMT control vector. Selection of A2UCOE.PGK.MGMT-transduced myeloid and lymphoid mature and progenitor cells was demonstrated in the peripheral blood, bone marrow, spleen, and thymus. Unlike the PGK and SFFV promoters used as controls, the A2UCOE.PGK promoter allowed for sustained vector copy number-related transgene expression throughout the experiment indicating an increased resistance to silencing, which was further confirmed by CpG methylation studies of the PGK promoter. Thus, our data support a potential role of the A2UCOE.PGK.MGMT-vector in future MGMT-based myeloprotection and chemoselection strategies, and underlines the suitability of the A2UCOE element to stabilize lentiviral transgene expression in hematopoietic gene therapy.
    Biomaterials 05/2014; 35(25). DOI:10.1016/j.biomaterials.2014.05.001 · 8.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The emergence of monoclonal antibody specific to human growth factor receptor marked the greatest achievement in human fight against cancer. By utilizing a specific antibody, cancer treatment nowadays is getting more specific and efficient. Despite its achievement, the main drawback of antibody therapy remains at its production level. Low yield and transient expression of antibody by mammalian host cells are among the problems discovered during antibody production. Many strategies have been implied to increase yield and stability of protein including improvement of vector expression system with DNA elements integration as well as manipulating the bioreactor environment to increase cell density and attain more products. Our study is currently focused on constructing a high expression vector system using matrix attachment region (MAR) element in targeted therapeutic monoclonal antibody production. In this study, a nuclear halo formation has been successfully optimized for CHO cells. A minimum time of 8 minutes is required for maximum nuclear halo formation, thus exposing the most significant sites containing MAR element in CHO genome. This preliminary step is crucial due to the fact that the nuclear halo formation and MAR elements isolation are specific for different types of cells. Subsequent works are currently being carried out to isolate the MAR element from CHO cells based on the time determined from nuclear halo formation. This work is going to be distinctive from previous studies as the MAR element will be predicted from the host cells genome. The mechanism of which the integrated functional MAR element can increase the antibody production even at random position is through up-regulation of gene transcription by adopting a DNA loop structure of nucleosomes that open the structure for specific transcription factor binding.
    The Open Conference Proceeding Journal, Dubai; 01/2013